Newsbenzinga
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
· Published
Article summary
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
An excerpt from the original article.
Comments —
Loading comments…